Lung cancer diagnosis is a challenge since it is also one of the most frequently diagnosed
cancers. Diagnostic challenges are deeply related to the development of personalized …

Recent therapeutic advances in oncology have been driven by the identification of tumour
genotype variations between patients, called interpatient heterogeneity, that predict the …

Two major treatment strategies employed in non-small cell lung cancer, NSCLC, are
tyrosine kinase inhibitors, TKIs, and immune checkpoint inhibitors, ICIs. The choice of …

PURPOSE Standard first-line therapy for EGFR-mutant advanced non–small-cell lung
cancer (NSCLC) is an epidermal growth factor receptor (EGFR)–directed oral tyrosine …

Tumors are characterized by somatic mutations that drive biological processes ultimately
reflected in tumor phenotype. With regard to radiographic phenotypes, generally …

All patients with metastatic lung, colorectal, pancreatic or head and neck cancers who
initially benefit from epidermal growth factor receptor (EGFR)-targeted therapies eventually …

Background In this study we retrospectively evaluated the capability of computed
tomography (CT)-based radiomic features to predict epidermal growth factor receptor …

Epidermal growth factor receptor (EGFR) is a transmembrane protein with cytoplasmic
kinase activity that transduces important growth factor signaling from the extracellular milieu …

Introduction Immunotherapy has improved outcomes for patients with non-small cell lung
cancer (NSCLC), yet durable clinical benefit (DCB) is experienced in only a fraction of …

Intratumor heterogeneity represents a major obstacle to effective cancer treatment and
personalized medicine. However, investigators are now elucidating intratumor heterogeneity …